MEDESIS PHARMA : TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM FIRST INCLUSION OF PATIENTS IN THE PHASE II CLINICAL STUDY
Subscribe

13 Jun 2022 08:00 CEST

Company Name

MEDESIS PHARMA S.A.

ISN

FR0010844464

Market

Euronext Growth

Symbol

ALMDP

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1081781_CP_NanoLithiuminclusionmalades_EN.pdf

Source

MEDESIS PHARMA

Provider

Les Echos

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Medesis Pharma SA published this content on 13 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 June 2022 06:12:05 UTC.